Cutting jobs over device tax is “nonsense,” says medtech CEO

MassDevice.com coverage of medical device tax

The medical device tax isn’t going to result in lost jobs if industry stakeholders play it right, according to speech therapy device maker Glottal Enterprises’ CEO.

In a letter written to the editor of the Syracuse Post-Standard, Martin Rothenberg did the math and concluded that the tax would result in marginal increases in product prices and "zero effect on sales" if the company could successfully market an effective product.

"It would surely not lead us to lay off employees or shift to overseas production," he wrote.

Rothenberg’s letter came in response to comments made by his home state’s Rep. Ann Marie Buerkle (R-N.Y.), who called out the device tax as a job killer.

Buerkle had cited Welch Allyn‘s decision to cut 275 jobs, which amounts to 10% of its global workforce, in order to cut costs ahead of the levy taking effect January 1.

"In claiming that it would significantly affect our sales, it is obvious that Buerkle is just using this issue to further a right-wing political agenda and attack the Affordable Care Act," Rothenberg wrote. "Either that or that she didn’t take the time to do the simple math needed to understand the effect of the act."

Welch Allyn is not alone in citing the tax as the catalyst for workforce cuts. Medical device companies Zimmer (NYSE:ZMH), which laid off about 50, Hill-Rom Holdings (NYSE:HRC), which cut about 200, and Stryker (NYSE:SYK) which cut more than 100, have all cited the tax as a primary justification for layoffs.

Rothenberg claimed that the tax would spur a nominal price increase on his products, which he could partically offset.

"Our company is currently putting out a new, unique medical device with a wide potential market among speech pathologists and otolaryngologists that will sell for about $350. The tax will add at most about $8 to the price," Rothenberg wrote. "In fact, since approximately half of our sales are outside the United States and therefore exempt from the tax, the tax on U.S. sales would be covered by a price increase of about $4."

Many medtech players expect to raise prices to make up for some of the costs of the tax, according to industry surveys, but pricing pressure on some medical devices, such as those in the cardiac rhythm management market, may prove difficult to overcome.

In addition, hospital groups have challenged the expected price increase, calling on the IRS to implement rules preventing medtech companies from hiking prices in response to the tax.

Rothenberg’s not the 1st to challenge the prevailing rhetoric on the medical device tax, a 2.3% levy on all U.S. sales of applicable technologies. A report released by Bloomberg earlier called out the medtech industry for its claims against the tax.

"Just about everything the medical-device industry says about the tax is either untrue or exaggerated," according to the report. "Lawmakers shouldn’t be so gullible, even when – perhaps especially when – industry lobbyists produce studies seeming to back their claims."

RSS From Medical Design & Outsourcing

  • Teknor Apex to showcase wide range of PVC compounds for medical devices at Medtec China
    Building on its international leadership role as a supplier of medical-grade PVC compounds, Teknor Apex Company has developed flexible and rigid formulations that address the special needs of device manufacturers. The company will highlight these capabilities at Medtec China 2015. “Teknor Apex produces or markets medical-grade PVC compounds in China, Singapore, Europe, and the United […]
  • The Raspberry Pi eco-system goes interstellar with the new Raspberry Pi Sense HAT
    Newark element14 has globally launched the latest addition to the expanding ecosystem of Raspberry Pi accessories, the Raspberry Pi Sense HAT, as featured in the ‘Astro Pi’ space mission. The Sense HAT will enable enthusiasts to control the same hardware used in space. The Sense HAT attaches to the Raspberry Pi board, and can be […]
  • CommScope completes acquisition of TE Connectivity’s Telecom
    CommScope Holding Company, has completed its previously announced acquisition of TE Connectivity’s Telecom, Enterprise and Wireless businesses, a leader in fiber optic connectivity for wireline and wireless networks. The all-cash transaction, valued at approximately $3 billion, strengthens CommScope’s position as a leading communications infrastructure provider with deeper resources to meet the world’s growing demand for network […]
  • SPI awards IKO Prosthetic Creative System the Student Design International Design Excellence Award
    SPI: The Plastics Industry Trade Association congratulated IKO Prosthetic Creative System for winning the SPI Student Design Award, part of the Industrial Designers Society of America’s (IDSA’s) International Design Excellence Awards (IDEA) program. The award was presented to IKO, an innovative, youth-focused prosthetic design company led by Chicago-based designer Carlos Torres, by SPI’s Senior Director of […]
  • New assay could revolutionize diagnosis and treatment of life-threatening disease
    Invasive Fungal Disease (IFD) is an emerging global health problem associated with high mortality rates in severely immunocompromised patients, such as those undergoing intensive chemotherapy or stem cell transplantation, and in patients suffering immune compromising conditions such as AIDS. The most common causative agents of this disease have been identified as Candida and Aspergillus species, […]
  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]

Leave a Reply